Nightstar’s $89 Million Initial Public Offering

Cooley advised Nightstar on its $86 million Initial Public Offering

Cooley partners Marc Recht (Picture), Brian Leaf, Div Gupta, Stephen Rosen and Ed Lukins led the cross-office team advising Nightstar on its $86 million IPO of 6,164,000 American Depositary Shares, which includes the full exercise of the underwriters’ option to purchase additional shares. Nightstar, which now trades on The NASDAQ Global Select Market under the symbol “NITE,” is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases.

Involved fees earner: Marc Recht – Cooley LLP; Brian Leaf – Cooley LLP; Div Gupta – Cooley LLP; Stephen Rosen – Cooley LLP; Ed Lukins – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Nightstar Therapeutics Limited;